Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase III randomized trial of niraparib versus physician's choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC4307-BCG and BIG5-13 Tryfonidis, K., Bogaerts, J., Martell, R. E., Sledge, G. W., Balmana, J., Audeh, M., Deleersnijder, A., Favorito, F., Agarwal, S., Rizzetto, G., Messina, C. M., Slaets, L., Goulioti, T., Tutt, A., Cameron, D. A., Turner, N. C. AMER SOC CLINICAL ONCOLOGY. 2014
View details for DOI 10.1200/jco.2014.32.15_suppl.tps659
View details for Web of Science ID 000358613201977